Literature DB >> 16184413

Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.

Mitsuki Miyata1, Kunio Kasugai, Tetsuya Ishikawa, Shinichi Kakumu, Masafumi Onishi, Takeshi Mori.   

Abstract

In this study we investigated the effect of rebamipide enema in patients with steroid-resistant and/or dependent ulcerative colitis. Rebamipide enemas were administered twice daily for a 12-week period; this treatment was further continued longer in patients who requested this. Disease activity index as reflecting the clinical condition and endoscopic index with histological grading were determined before and after the treatment period. Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. Moreover, seven of 11 patients requested long-term medication, the longest medication term being 80 weeks. These results medicated that rebamipide enemas may be effective in patients with steroid-resistant and/or dependent ulcerative colitis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16184413     DOI： 10.1007/s10620-005-2816-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  25 in total

1.  Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide.

Authors:  T Matysiak-Budnik; A Thomas-Collignon; F Mégraud; M Heyman
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis.

Authors:  C H Florén; C Benoni; R Willén
Journal:  Scand J Gastroenterol       Date:  1987-05       Impact factor: 2.423

3.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

4.  Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.

Authors:  P G Farup; T A Hinterleitner; M Lukás; X Hébuterne; D Rachmilewitz; M Campieri; R Meier; R Keller; B Rathbone; E Oddsson
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

5.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

6.  Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis.

Authors:  T Matysiak-Budnik; A de Mascarel; M Abely; K Mayo; M Heyman; F Mégraud
Journal:  Scand J Gastroenterol       Date:  2000-05       Impact factor: 2.423

7.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

Authors:  S Hanauer; J Schwartz; M Robinson; W Roufail; S Arora; J Cello; M Safdi
Journal:  Am J Gastroenterol       Date:  1993-08       Impact factor: 10.864

8.  Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study.

Authors:  Y Naito; T Yoshikawa; T Tanigawa; K Sakurai; K Yamasaki; M Uchida; M Kondo
Journal:  Free Radic Biol Med       Date:  1995-01       Impact factor: 7.376

9.  Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance.

Authors:  T Yoshikawa; Y Naito; T Tanigawa; M Kondo
Journal:  Arzneimittelforschung       Date:  1993-03

10.  An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.

Authors: 
Journal:  Ann Intern Med       Date:  1996-01-15       Impact factor: 25.391
View more
  4 in total

1.  Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.

Authors:  Tomohisa Takagi; Yuji Naito; Kazuhiko Uchiyama; Toshimitsu Okuda; Katsura Mizushima; Takahiro Suzuki; Osamu Handa; Takeshi Ishikawa; Nobuaki Yagi; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

2.  Novel topical therapies for distal colitis.

Authors:  Ian Craig Lawrance
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

3.  Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier.

Authors:  Bei-Bei Huang; Guo-Feng Li; Jing-Hui Luo; Lian Duan; Kishimoto Nobuaki; Yamamoto Akira
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

4.  Rebampide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed.

Authors:  Tae Oh Kim; Geun Am Song; Sun Mi Lee; Gwang Ha Kim; Jeong Heo; Dae Hwan Kang; Mong Cho
Journal:  Int J Colorectal Dis       Date:  2008-03-08       Impact factor: 2.571
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.